Stratipath wins innovation prize for advances in AI-based precision oncology

AI-precision oncology pioneers Stratipath have been awarded the Athena Prize, one of Sweden’s most prestigious awards for innovation in health care for the development of their AI-based solution for improved prognostic analysis of breast cancer, using only microscopy images. The jury praised the company’s ‘impressive achievement’, in taking basic academic research through to the first approval for clinical use earlier this year. The tool will provide significant benefits for healthcare systems and individual patients, by enabling cost-effective and equivalent precision medical diagnostics.

Photo: Rebecka Rynefelt.

”We are very proud of our solution and what we have achieved so far. On top of getting public recognition through the Athena Prize, we are also delighted to be receiving fantastic feedback from our customers who are excited at the prospects of its clinical roll-out.” says Fredrik Wetterhall, CEO of Stratipath.

The Swedish Athena prize
The Swedish Athena Prize is awarded by the Swedish Research Council, Forte, Swedish Medtech, Sweden’s Municipalities and Regions, Vinnova (the Swedish innovation agency) and the publisher Dagens Medicin (Daily medicine) together with Sweden’s pharmaceutical industry trade association LIF.

Professor Jonas Bergh, will be leading our scientific advisory board

Stratipath is happy to announce that one of the most prominent breast oncologists, Professor Jonas Bergh, will be leading the company’s scientific advisory board. As Stratipath is entering the clinical phase with its first-in-class, CE-IVD solution for AI-driven risk profiling, Stratipath breast and at the same time ramping up the research and development efforts for future solutions, the scientific advisory board will play a crucial role in the company’s development.

Read More »

The Swedish deep-tech company Stratipath announces its integration with Sectra, one of the most expanding PACS systems for digital pathology

Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, today announced that it has released its integration with international medical imaging IT company Sectra and their digital pathology solution. This means that Sectra users can use Stratipath’s solution Stratipath Breast within an already existing digital pathology workflow. The application is featured in Sectra Amplifier Marketplace and purchased directly from Stratipath.

Read More »

Government grant to provide more accurate breast cancer diagnosis

Vinnova grants SEK 20 million to the Swedish AI Precision Pathology (SwAIPP) consortia to develop and implement AI-based precision diagnostics in cancer care. The consortia consist of Stratipath, Karolinska Institutet, the pathology clinics in the Kalmar, Västmanland and Skåne regions, Microsoft, Roche Diagnostics, Philips, Bröstcancerförbundet, Prevas and Helseplan.

Read More »

Annals of Oncology

analysis can stratify intermediate-grade breast cancers into low or high grade. This has strong prognostic value and potential to revolutionize breast pathology.

Read More »

This website uses cookies. By continuing to use this site, you accept our use of cookies.  Learn more